Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-65
Last updated

Report documents

  1. Extract of dossier assessment

    Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 413 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 413 kB, EN, not accessible)

  2. Dossier assessment

    Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 644 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 644 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with follicular lymphoma who did not respond to treatment with rituximab alone or in combination with other drugs, or whose disease has progressed during or up to 6 months after treatment with rituximab

Result of dossier assessment:

Added benefit not proven.

Project details

Project no.
A21-65
Commission
Commission awarded on 12.05.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Obinutuzumab (non-pretreated advanced follicular lymphoma) - Assessment according to §35a (1), Sentence 11, Social Code Book V

    Project no.
    G17-11
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Obinutuzumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V

    Project no.
    G16-07
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Obinituzumab - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)

    Project no.
    G14-08
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Obinutuzumab (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-64
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-66
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page